Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
01 2020
Historique:
received: 15 09 2019
revised: 06 11 2019
accepted: 11 11 2019
pubmed: 27 11 2019
medline: 25 2 2020
entrez: 27 11 2019
Statut: ppublish

Résumé

The majority of endometrial cancers are detected early with a favourable prognosis. However, for patients with advanced disease, chemotherapy response rates and overall survival remains poor. The endometrial cancer population is typically elderly with multiple co-morbidities and aggressive cytotoxic therapy may be hazardous. Therefore, there is an urgent need to define optimal treatment strategies for advanced and recurrent disease and personalise therapy based on individual tumour and patient characteristics. Three-dimensional (3D) models that preserve the tumour microenvironment and tumour-stromal interactions are increasingly important for translational research with the advent of immunotherapy and molecularly targeted agents. 3D patient-relevant pre-clinical models in endometrial cancer include spheroids, patient-derived organoids, microfluidic systems, patient-derived xenografts and patient-derived explants. Here we present a review of available 3D modelling systems in endometrial cancers, highlighting their current use, advantages, disadvantages and applications to translational research with a focus on the power of the patient-derived explant platform.

Identifiants

pubmed: 31767187
pii: S0090-8258(19)31671-3
doi: 10.1016/j.ygyno.2019.11.020
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-259

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00025/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14117
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C10604/A25151
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_16051
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15045
Pays : United Kingdom

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Anna Collins (A)

Leicester Cancer Research Centre, University of Leicester, Clinical Sciences Building, Leicester LE2 7LX, UK.

Gareth J Miles (GJ)

Leicester Cancer Research Centre, University of Leicester, Clinical Sciences Building, Leicester LE2 7LX, UK.

Joanna Wood (J)

Leicester Cancer Research Centre, University of Leicester, Clinical Sciences Building, Leicester LE2 7LX, UK.

Marion MacFarlane (M)

MRC Toxicology Unit, Hodgkin Building, Lancaster Road, Leicester LE1 9HN, UK. Electronic address: mm21@le.ac.uk.

Catrin Pritchard (C)

Leicester Cancer Research Centre, University of Leicester, Clinical Sciences Building, Leicester LE2 7LX, UK. Electronic address: cap8@le.ac.uk.

Esther Moss (E)

Leicester Cancer Research Centre, University of Leicester, Clinical Sciences Building, Leicester LE2 7LX, UK. Electronic address: em321@le.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH